2023年1月6日

美國東部時間2023年1月6日布裏斯班，加利福尼亞州(GLOBE NEWSWIRE) - Annexon, Inc.(納斯達克:ANNX公司是一家臨床階段的生物製藥公司，正在為經典補體介導的自身免疫性疾病、神經退行性疾病和眼科疾病患者開發一種新的補體藥物。該公司今天宣布，Dean“Rick”Artis博士被任命為首席科學官(CSO)，接替Larry C. Mattheakis博士。Artis博士最近擔任Octant Bio的CSO。他領導Annexon公司發現了小分子經典補體抑製劑，包括ANX1502。“自成立以來，我們一直致力於為患有補體介導疾病的患者提供改變遊戲規則的治療方法。我為我們迄今取得的進展感到自豪，並感謝拉裏的貢獻和領導，幫助我們走到這一步，”Annexon總裁兼首席執行官道格拉斯·洛夫(Douglas Love)說。“隨著我們推進廣泛的補充管道，未來幾年將對我們公司進行轉型，幾項中後期試驗正在進行中。很高興歡迎Rick回到Annexon團隊，以CSO的身份領導我們的研究工作。他是一位經驗豐富的高管，橫跨計算和基於結構的藥物設計、藥物化學和轉化臨床開發工作，他發現了我們的第一個小分子，ANX1502，是我們公司的一個裏程碑式的時刻。他帶來了成功的記錄，這將幫助我們進一步擴大我們的科學潛力，並為我們的使命而努力，為有需要的患者帶來新的治療方法。”作為Annexon的CSO, Artis博士將負責領導所有的研究工作，特別強調小分子研究的擴展和公司強大管道的進一步建設。 Prior to his most recent role as CSO at Octant, Dr. Artis served as senior vice president, chemistry at Annexon, senior vice president, research at Elan Pharmaceuticals, vice president, lead generation at Plexxikon and held positions of increasing responsibility at Genentech and Syntex. He has been responsible for efforts from target validation and screening to early development and has discovery-to-clinic experience in several therapeutic areas, including neurodegenerative and metabolic diseases and oncology. He has led efforts at the forefront of fragment-based drug discovery and is a co-inventor of the first drug derived from these approaches, vemurafenib for the treatment of metastatic melanoma. He has co-authored over 45 papers, been recognized as a co-inventor on 45 issued U.S. patents and made direct contributions to seven molecules that have reached various stages of clinical development, including two that have received marketing approval. He received a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Yale University. “Annexon has built an impressive pipeline of classical complement inhibitors for the body, brain and eye,” said Dr. Artis. “This is an exciting time for the company as we expand into late-stage and pivotal development with many of our programs and advance a number of exciting earlier stage opportunities with significant potential. I am thrilled to partner with the team to continue building upon the pioneering research at Annexon to address complement-mediated diseases.” About Annexon Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late-stage clinical trials, with clinical data readouts anticipated throughout 2023 and beyond. Investor Contact: